| Item Type | Name |
|
Concept
|
Adjuvants, Immunologic
|
|
Concept
|
Adrenal Cortex Hormones
|
|
Concept
|
Alanine Transaminase
|
|
Concept
|
Anti-Infective Agents
|
|
Concept
|
Antidiarrheals
|
|
Concept
|
Antigens, Neoplasm
|
|
Concept
|
Alkaline Phosphatase
|
|
Concept
|
alpha-Fetoproteins
|
|
Concept
|
Cyclic AMP
|
|
Concept
|
Allopurinol
|
|
Concept
|
Blood Proteins
|
|
Concept
|
Antifoaming Agents
|
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Anticoagulants
|
|
Concept
|
Anti-Inflammatory Agents, Non-Steroidal
|
|
Concept
|
Anti-Ulcer Agents
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Antigens, Helminth
|
|
Concept
|
Cyclosporins
|
|
Concept
|
Anti-Inflammatory Agents
|
|
Concept
|
Antimetabolites
|
|
Concept
|
Base Sequence
|
|
Concept
|
Cephalosporins
|
|
Concept
|
Aspartate Aminotransferases
|
|
Concept
|
Aspirin
|
|
Concept
|
Azathioprine
|
|
Concept
|
Bacterial Toxins
|
|
Concept
|
Autoantibodies
|
|
Concept
|
Bacterial Proteins
|
|
Concept
|
Drug Tolerance
|
|
Concept
|
Bilirubin
|
|
Concept
|
Biological Products
|
|
Concept
|
Gastrointestinal Agents
|
|
Concept
|
Ciprofloxacin
|
|
Concept
|
C-Reactive Protein
|
|
Concept
|
Carnitine
|
|
Concept
|
Guanine Nucleotides
|
|
Concept
|
Hemoglobins
|
|
Concept
|
Histamine H1 Antagonists
|
|
Concept
|
Consumer Product Safety
|
|
Concept
|
Contraceptives, Oral
|
|
Concept
|
DNA-Binding Proteins
|
|
Concept
|
Domperidone
|
|
Concept
|
Drug Industry
|
|
Concept
|
Drug Synergism
|
|
Concept
|
Electrolytes
|
|
Concept
|
Diphenhydramine
|
|
Concept
|
Immunoglobulin Fab Fragments
|
|
Concept
|
Immunosuppressive Agents
|
|
Concept
|
Curcumin
|
|
Concept
|
Drug Hypersensitivity
|
|
Concept
|
Cyclophosphamide
|
|
Concept
|
Cytotoxins
|
|
Concept
|
Emulsions
|
|
Concept
|
Glucocorticoids
|
|
Concept
|
Glycoproteins
|
|
Concept
|
Enzyme Inhibitors
|
|
Concept
|
Immunologic Factors
|
|
Concept
|
Cycloserine
|
|
Concept
|
DNA
|
|
Concept
|
Drug Interactions
|
|
Concept
|
Drug Resistance
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Food
|
|
Concept
|
Indoles
|
|
Concept
|
Methyltransferases
|
|
Concept
|
Fluorouracil
|
|
Concept
|
Gases
|
|
Concept
|
Fibroblast Growth Factors
|
|
Concept
|
Cyclic GMP
|
|
Concept
|
Aminosalicylic Acid
|
|
Concept
|
Dose-Response Relationship, Drug
|
|
Concept
|
Drug Combinations
|
|
Concept
|
Pharmaceutical Preparations
|
|
Concept
|
Insulin-Like Growth Factor I
|
|
Concept
|
HLA-DR Antigens
|
|
Concept
|
Hydrocortisone
|
|
Concept
|
Fatty Acids, Volatile
|
|
Concept
|
Folic Acid Antagonists
|
|
Concept
|
Lactoferrin
|
|
Concept
|
Histamine Antagonists
|
|
Concept
|
HLA-DQ Antigens
|
|
Concept
|
Leukotriene B4
|
|
Concept
|
Midazolam
|
|
Concept
|
Oxadiazoles
|
|
Concept
|
Methotrexate
|
|
Concept
|
Methylprednisolone
|
|
Concept
|
Interleukin-3
|
|
Concept
|
Phosphodiesterase Inhibitors
|
|
Concept
|
Lipopolysaccharides
|
|
Concept
|
Safety
|
|
Concept
|
Salicylates
|
|
Concept
|
Melphalan
|
|
Concept
|
Phytohemagglutinins
|
|
Concept
|
Suppositories
|
|
Concept
|
Polyvinyls
|
|
Concept
|
Prednisolone
|
|
Concept
|
Prednisone
|
|
Concept
|
Proteins
|
|
Concept
|
Pyridines
|
|
Concept
|
Immunoglobulin G
|
|
Concept
|
Reference Standards
|
|
Concept
|
Purines
|
|
Concept
|
Quinolines
|
|
Concept
|
Cadherins
|
|
Concept
|
Interleukin-6
|
|
Concept
|
Sulfasalazine
|
|
Concept
|
Spiro Compounds
|
|
Concept
|
Thiotepa
|
|
Concept
|
Thalidomide
|
|
Concept
|
Sulfapyridine
|
|
Concept
|
Indans
|
|
Concept
|
Thionucleotides
|
|
Concept
|
United States Food and Drug Administration
|
|
Concept
|
Lipoxygenase Inhibitors
|
|
Concept
|
Trinitrobenzenesulfonic Acid
|
|
Concept
|
Biomarkers, Tumor
|
|
Concept
|
Tumor Necrosis Factor-alpha
|
|
Concept
|
Thioguanine
|
|
Concept
|
Drug Design
|
|
Concept
|
CD28 Antigens
|
|
Concept
|
Mercaptopurine
|
|
Concept
|
Loperamide
|
|
Concept
|
Thyroxine
|
|
Concept
|
Nicotinic Agonists
|
|
Concept
|
Antibodies, Antineutrophil Cytoplasmic
|
|
Concept
|
Vitamins
|
|
Concept
|
NF-kappa B
|
|
Concept
|
Cell Adhesion Molecules
|
|
Concept
|
Methoxsalen
|
|
Concept
|
Antigens, CD
|
|
Concept
|
Interleukin-8
|
|
Concept
|
Paclitaxel
|
|
Concept
|
Interleukin-10
|
|
Concept
|
Drug Approval
|
|
Concept
|
Drug Delivery Systems
|
|
Concept
|
Tacrolimus
|
|
Concept
|
Drugs, Generic
|
|
Concept
|
Dextran Sulfate
|
|
Concept
|
Prostate-Specific Antigen
|
|
Concept
|
Safety Management
|
|
Concept
|
Mycophenolic Acid
|
|
Concept
|
Orosomucoid
|
|
Concept
|
Photosensitizing Agents
|
|
Concept
|
Receptors, Tumor Necrosis Factor
|
|
Concept
|
DNA, Complementary
|
|
Concept
|
Interleukin-12
|
|
Concept
|
Apoptosis Regulatory Proteins
|
|
Concept
|
Antirheumatic Agents
|
|
Concept
|
Antineoplastic Agents, Alkylating
|
|
Concept
|
Cyclooxygenase 2 Inhibitors
|
|
Concept
|
Calcineurin
|
|
Concept
|
Measles-Mumps-Rubella Vaccine
|
|
Concept
|
Interleukin-23
|
|
Concept
|
Immunoconjugates
|
|
Concept
|
Reactive Oxygen Species
|
|
Concept
|
Collagen Type I
|
|
Concept
|
Intercellular Signaling Peptides and Proteins
|
|
Concept
|
Integrin alpha Chains
|
|
Concept
|
B7-H1 Antigen
|
|
Concept
|
Leukocyte L1 Antigen Complex
|
|
Concept
|
Mesalamine
|
|
Concept
|
Budesonide
|
|
Concept
|
Cisapride
|
|
Concept
|
Cell Cycle Proteins
|
|
Concept
|
Nod1 Signaling Adaptor Protein
|
|
Concept
|
Interleukin-1beta
|
|
Concept
|
Thrombospondins
|
|
Concept
|
Sirolimus
|
|
Concept
|
I-kappa B Proteins
|
|
Concept
|
Phenylhydrazines
|
|
Concept
|
Polyethylene Glycols
|
|
Concept
|
Piperidines
|
|
Concept
|
Saccharomyces cerevisiae Proteins
|
|
Concept
|
Prodrugs
|
|
Concept
|
Pyrimidines
|
|
Concept
|
Recombinant Proteins
|
|
Concept
|
Pyrroles
|
|
Concept
|
Rifamycins
|
|
Concept
|
RNA, Ribosomal, 16S
|
|
Concept
|
Serum Albumin
|
|
Concept
|
RNA, Messenger
|
|
Concept
|
Thiazolidinediones
|
|
Concept
|
Integrin alpha4
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Tumor Necrosis Factors
|
|
Concept
|
CTLA-4 Antigen
|
|
Concept
|
Simethicone
|
|
Concept
|
Interleukin-12 Subunit p40
|
|
Concept
|
Steroids
|
|
Concept
|
Vitamin D
|
|
Concept
|
Adaptor Proteins, Signal Transducing
|
|
Concept
|
Suspensions
|
|
Concept
|
Tablets
|
|
Concept
|
3',5'-Cyclic-AMP Phosphodiesterases
|
|
Concept
|
Rad51 Recombinase
|
|
Concept
|
Thiazoles
|
|
Concept
|
Cyclosporine
|
|
Concept
|
Drug Monitoring
|
|
Concept
|
Interleukin-11
|
|
Concept
|
Interferon-beta
|
|
Concept
|
CD3 Complex
|
|
Concept
|
Receptors, Calcitriol
|
|
Concept
|
Homeodomain Proteins
|
|
Concept
|
Chemical and Drug Induced Liver Injury
|
|
Concept
|
Tumor Suppressor Proteins
|
|
Concept
|
Caveolin 1
|
|
Concept
|
HLA-DRB1 Chains
|
|
Concept
|
Nod2 Signaling Adaptor Protein
|
|
Concept
|
Cyclic Nucleotide Phosphodiesterases, Type 4
|
|
Concept
|
Programmed Cell Death 1 Receptor
|
|
Concept
|
Intracellular Signaling Peptides and Proteins
|
|
Concept
|
Fibroblast Growth Factor 10
|
|
Concept
|
Cytochrome P-450 CYP3A
|
|
Concept
|
Matrix Metalloproteinase 14
|
|
Concept
|
Ghrelin
|
|
Concept
|
Biosimilar Pharmaceuticals
|
|
Concept
|
Allergens
|
|
Concept
|
Aminosalicylic Acids
|
|
Concept
|
Anti-Bacterial Agents
|
|
Concept
|
Antibodies
|
|
Concept
|
Antibodies, Antinuclear
|
|
Concept
|
Biological Factors
|
|
Concept
|
Capsules
|
|
Concept
|
Carbohydrates
|
|
Concept
|
Carbon
|
|
Concept
|
Carrier Proteins
|
|
Concept
|
Cytosine
|
|
Concept
|
Delayed-Action Preparations
|
|
Concept
|
Doxorubicin
|
|
Concept
|
Drug Administration Schedule
|
|
Concept
|
Fat Emulsions, Intravenous
|
|
Concept
|
Folic Acid
|
|
Concept
|
Injections
|
|
Concept
|
Legislation, Drug
|
|
Concept
|
Metronidazole
|
|
Concept
|
Nicotine
|
|
Concept
|
Nuclear Proteins
|
|
Concept
|
Oxides
|
|
Concept
|
Pentanoic Acids
|
|
Concept
|
Polymethacrylic Acids
|
|
Concept
|
Prostaglandin Antagonists
|
|
Concept
|
Recombinant Fusion Proteins
|
|
Concept
|
Integrins
|
|
Concept
|
Granulocyte-Macrophage Colony-Stimulating Factor
|
|
Concept
|
MicroRNAs
|
|
Concept
|
Receptors, Lysosphingolipid
|
|
Concept
|
Proton Pump Inhibitors
|
|
Concept
|
Drug Substitution
|
|
Concept
|
Patient Safety
|
|
Academic Article
|
Cyclosporin for severe ulcerative colitis: a user's guide.
|
|
Academic Article
|
Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group.
|
|
Academic Article
|
No butts about it: put the fire out by lighting up.
|
|
Academic Article
|
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
|
|
Academic Article
|
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.
|
|
Academic Article
|
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
|
|
Academic Article
|
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.
|
|
Academic Article
|
Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group.
|
|
Academic Article
|
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
|
|
Academic Article
|
Infliximab for the treatment of fistulas in patients with Crohn's disease.
|
|
Academic Article
|
Comparative tolerability of treatments for inflammatory bowel disease.
|
|
Academic Article
|
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.
|
|
Academic Article
|
Sulfasalazine vs. steroids in Crohn's disease: David vs. Goliath?
|
|
Academic Article
|
Updating the approach to Crohn's disease.
|
|
Academic Article
|
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
|
|
Academic Article
|
Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
|
|
Academic Article
|
Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease.
|
|
Academic Article
|
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.
|
|
Academic Article
|
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
|
|
Academic Article
|
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
|
|
Academic Article
|
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
|
|
Academic Article
|
Immunogenicity of infliximab in Crohn's disease.
|
|
Academic Article
|
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
|
|
Academic Article
|
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
|
|
Academic Article
|
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
|
|
Academic Article
|
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
|
|
Academic Article
|
Treatment of inflammatory bowel disease: safety and tolerability issues.
|
|
Academic Article
|
Review article: the long-term management of ulcerative colitis.
|
|
Academic Article
|
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
|
|
Academic Article
|
COLAL-PRED Alizyme.
|
|
Academic Article
|
The state of the art in the management of inflammatory bowel disease.
|
|
Academic Article
|
Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis.
|
|
Academic Article
|
Review article: aminosalicylates in inflammatory bowel disease.
|
|
Academic Article
|
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
|
|
Academic Article
|
Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease.
|
|
Academic Article
|
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies.
|
|
Academic Article
|
Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
|
|
Academic Article
|
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
|
|
Academic Article
|
Safety first: messages from Digestive Disease Week 2006.
|
|
Academic Article
|
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
|
|
Academic Article
|
Medical management of Crohn's disease.
|
|
Academic Article
|
Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down".
|
|
Academic Article
|
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
|
|
Academic Article
|
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
|
|
Academic Article
|
Balancing drug availability and patient safety.
|
|
Academic Article
|
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.
|
|
Academic Article
|
Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort.
|
|
Academic Article
|
Conflicts.
|
|
Academic Article
|
Controversies with aminosalicylates in inflammatory bowel disease.
|
|
Academic Article
|
Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
|
|
Academic Article
|
Selecting appropriate anti-TNF agents in inflammatory bowel disease.
|
|
Academic Article
|
Devolving therapeutic pyramids.
|
|
Academic Article
|
A generic problem.
|
|
Academic Article
|
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
|
|
Academic Article
|
Addicted to acid suppression.
|
|
Academic Article
|
Medical management of Crohn's disease: treatment algorithms 2009.
|
|
Academic Article
|
Indecent exposures.
|
|
Academic Article
|
Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease.
|
|
Academic Article
|
Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
|
|
Academic Article
|
Where do our priorities lie?
|
|
Academic Article
|
Maintenance therapy with certolizumab pegol for Crohn's disease.
|
|
Academic Article
|
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
|
|
Academic Article
|
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.
|
|
Academic Article
|
Calcineurin inhibition in severe ulcerative colitis: lost in translation?
|
|
Academic Article
|
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.
|
|
Academic Article
|
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
|
|
Academic Article
|
Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction.
|
|
Academic Article
|
Treatment of Crohn's disease: the "long" of it.
|
|
Academic Article
|
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study.
|
|
Academic Article
|
Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.
|
|
Academic Article
|
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
|
|
Academic Article
|
Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study.
|
|
Academic Article
|
Outsourcing clinical trials.
|
|
Academic Article
|
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.
|
|
Academic Article
|
Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study.
|
|
Academic Article
|
Selected individual therapeutic problems in inflammatory bowel disease.
|
|
Academic Article
|
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
|
|
Academic Article
|
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
|
|
Academic Article
|
Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease.
|
|
Academic Article
|
Acute leukemia following inflammatory bowel disease.
|
|
Academic Article
|
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
|
|
Academic Article
|
Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease.
|
|
Academic Article
|
Balancing drug availability and patient safety.
|
|
Academic Article
|
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
|
|
Academic Article
|
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
|
|
Academic Article
|
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
|
|
Academic Article
|
pANCA and classification resistance in ulcerative colitis.
|
|
Academic Article
|
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
|
|
Academic Article
|
Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease.
|
|
Academic Article
|
Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid.
|
|
Academic Article
|
Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin.
|
|
Academic Article
|
Mesalamine capsules enhance the quality of life for patients with ulcerative colitis.
|
|
Academic Article
|
Intravenous cyclosporin in ulcerative colitis: a five-year experience.
|
|
Academic Article
|
Review article: safety of infliximab in clinical trials.
|
|
Academic Article
|
Inflammatory bowel disease revisited: newer drugs.
|
|
Academic Article
|
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
|
|
Academic Article
|
Steroids as recreational drugs.
|
|
Academic Article
|
Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
|
|
Academic Article
|
Uncertainty.
|
|
Academic Article
|
Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease.
|
|
Academic Article
|
More food for thought.
|
|
Academic Article
|
Quid pro quo and the pharmascolds.
|
|
Academic Article
|
Quality indicators for inflammatory bowel disease: development of process and outcome measures.
|
|
Academic Article
|
Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
|
|
Academic Article
|
Drug Trials in Inflammatory Bowel Diseases 1993-1995: A Survey Conducted by the IOIBD.
|
|
Academic Article
|
Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy.
|
|
Academic Article
|
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
|
|
Academic Article
|
Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study.
|
|
Academic Article
|
Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease.
|
|
Academic Article
|
Heading back to the trough (levels of biologics in IBD).
|
|
Academic Article
|
In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease.
|
|
Academic Article
|
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease.
|
|
Academic Article
|
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
|
|
Academic Article
|
Vedolizumab as induction and maintenance therapy for Crohn's disease.
|
|
Academic Article
|
American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
|
|
Academic Article
|
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
|
|
Academic Article
|
Treat to target: a proposed new paradigm for the management of Crohn's disease.
|
|
Academic Article
|
Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study.
|
|
Academic Article
|
Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.
|
|
Academic Article
|
Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes.
|
|
Academic Article
|
Targeting interleukin 23 for Crohn's disease: finding the right drug for the right patient.
|
|
Academic Article
|
Optimizing pharmacologic management of inflammatory bowel disease.
|
|
Academic Article
|
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
|
|
Academic Article
|
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.
|
|
Academic Article
|
Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy.
|
|
Academic Article
|
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
|
|
Academic Article
|
Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
|
|
Academic Article
|
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
|
|
Academic Article
|
Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?
|
|
Academic Article
|
Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).
|
|
Academic Article
|
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
|
|
Academic Article
|
Perspectives of Clinicians in the United States and Europe on Monitoring Levels of Biologic Agents in Patients Receiving Biologic Therapies for Inflammatory Bowel Diseases.
|
|
Academic Article
|
Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
|
|
Academic Article
|
Drug-Induced Colitis.
|
|
Academic Article
|
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.
|
|
Academic Article
|
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
|
|
Academic Article
|
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
|
|
Academic Article
|
Review article: drug-induced small bowel injury.
|
|
Academic Article
|
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
|
|
Academic Article
|
Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate).
|
|
Academic Article
|
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
|
|
Academic Article
|
Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis.
|
|
Academic Article
|
Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring.
|
|
Academic Article
|
Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease.
|
|
Concept
|
Zonula Occludens-1 Protein
|
|
Concept
|
Occludin
|
|
Concept
|
Drug-Related Side Effects and Adverse Reactions
|
|
Concept
|
Calcineurin Inhibitors
|
|
Grant
|
Multi-site Trial of Azathioprine Dosing in Crohn Disease
|
|
Grant
|
Multi-site Trial of Azathioprine Dosing in Crohn Disease
|
|
Academic Article
|
Efficacy and Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.
|